
Updated Data From Phase 1 Trials Support Shifts in the Lung Cancer Treatment Paradigm
Among the treatments that are slowly moving the needle in the non–small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) treatment landscapes are datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) plus rilvegostomig (formerly …